Propranolol for Kaposi sarcoma
Treatments studied
Part of Cancer, Infections clinical trials.
This trial tests whether propranolol, a beta-blocker medicine, can treat Kaposi sarcoma (KS), a type of cancer that causes lesions on the skin or mouth. It may help people with mild-to-moderate KS, including those with HIV, if their disease has not improved or has worsened despite other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Kaposi sarcoma confirmed by a biopsy, with at least one measurable lesion.
- Your disease must be mild to moderate (not advanced) — for example, limited skin or mouth lesions, or mild swelling, but not spread to organs or causing major swelling that impairs function.
- You must be on antiretroviral therapy (ART) for HIV for at least 12 weeks, if you are HIV-positive, and your KS must not be improving on ART (or if on ART 12–24 weeks, you must need further treatment).
- You must have adequate organ function (e.g., normal bilirubin, adequate kidney and blood counts).
- You must not have asthma, diabetes, severe heart problems, or a history of allergic reaction to propranolol or other beta-blockers.
- If you are a woman able to have children, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This trial compares two chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, to see which works better for HIV-related Kaposi sarcoma. It aims to find a more effective treatment to shrink skin lesions and improve quality of life.
This Phase 1/2 study tests the medicine abemaciclib to shrink Kaposi sarcoma (KS) lesions and control the disease. It includes both people with HIV and people without HIV, and may help when KS has not responded well to prior treatment or when certain KS stages are present.
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
Hear when a new Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.